Literature DB >> 22704918

Association of a protective paraoxonase 1 (PON1) polymorphism in Parkinson's disease.

Andrea Carmine Belin1, Caroline Ran, Anna Anvret, Silvia Paddock, Marie Westerlund, Anna Håkansson, Hans Nissbrandt, Peter Söderkvist, Nil Dizdar, Ahmad Ahmadi, Maria Anvret, Thomas Willows, Olof Sydow, Dagmar Galter.   

Abstract

Pesticide exposure has been suggested to increase the risk to develop Parkinson's disease (PD). The arylesterase paraoxonase 1 (PON1) is mainly expressed in the liver and hydrolyzes organophosphates such as pesticides. The polymorphism Leu54Met (rs854560) in PON1, impairing enzyme activity and leading to decreased PON1 expression levels, has been reported to be associated with Parkinson's disease (PD). PON1 is part of a cluster on chromosome 7q21.3 together with PON2 and PON3. We investigated the occurrence of four additional polymorphisms in PON1 and two in PON2 in a Swedish PD case-control material. We found a significant association (p=0.007) with a PON1 promoter polymorphism, rs854571. The minor allele was more common among controls than PD cases which suggest a protective effect. This is strengthened by the fact that rs854571 is in strong linkage disequilibrium with another PON1 promoter polymorphism, rs854572, reported to increase PON1 gene expression. Our findings support the hypothesis that PON1 is involved in the etiology of PD and that higher PON1 levels are reducing the risk for PD.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22704918     DOI: 10.1016/j.neulet.2012.06.007

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

1.  Functional paraoxonase 1 variants modify the risk of Parkinson's disease due to organophosphate exposure.

Authors:  Pei-Chen Lee; Shannon L Rhodes; Janet S Sinsheimer; Jeff Bronstein; Beate Ritz
Journal:  Environ Int       Date:  2013-04-16       Impact factor: 9.621

Review 2.  Paraoxonase 1 in neurological disorders.

Authors:  Teresita Menini; Alejandro Gugliucci
Journal:  Redox Rep       Date:  2013-11-12       Impact factor: 4.412

3.  Association of a BACE1 Gene Polymorphism with Parkinson's Disease in a Norwegian Population.

Authors:  Johannes Lange; Kristin Aaser Lunde; Camilla Sletten; Simon Geir Møller; Ole-Bjørn Tysnes; Guido Alves; Jan Petter Larsen; Jodi Maple-Grødem
Journal:  Parkinsons Dis       Date:  2015-12-14

4.  K-variant BCHE and pesticide exposure: Gene-environment interactions in a case-control study of Parkinson's disease in Egypt.

Authors:  Thomas W Rösler; Mohamed Salama; Ali S Shalash; Eman M Khedr; Abdelhalim El-Tantawy; Gharib Fawi; Amal El-Motayam; Ehab El-Seidy; Mohamed El-Sherif; Mohamed El-Gamal; Mohamed Moharram; Mohammad El-Kattan; Muhammad Abdel-Naby; Samia Ashour; Ulrich Müller; Astrid Dempfle; Gregor Kuhlenbäumer; Günter U Höglinger
Journal:  Sci Rep       Date:  2018-11-08       Impact factor: 4.379

5.  Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?

Authors:  María C Leal; Juan C Casabona; Mariana Puntel; Fernando J Pitossi
Journal:  Front Cell Neurosci       Date:  2013-04-29       Impact factor: 5.505

6.  Structural and Functional Changes of Reconstituted High-Density Lipoprotein (HDL) by Incorporation of α-synuclein: A Potent Antioxidant and Anti-Glycation Activity of α-synuclein and apoA-I in HDL at High Molar Ratio of α-synuclein.

Authors:  Kyung-Hyun Cho
Journal:  Molecules       Date:  2021-12-10       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.